Pharma channel feed

No­var­tis shoots for ear­ly OK of a ‘break­through’ blood can­cer drug af­ter re­vers­ing or­gan dam­age in tri­al

9 years ago
R&D

Trou­bled In­fin­i­ty ax­es 100 staffers, shut­ters tri­als and re­wards top ex­ecs af­ter Ab­b­Vie walks away from deal

9 years ago

Reg­u­lus craters af­ter FDA slaps a hold on hep C RNA drug fol­low­ing 2nd case of jaun­dice

9 years ago

Third time the charm? An­a­lyst says a mar­ket­ing de­ci­sion is “im­mi­nent” for Sarep­ta’s Duchenne drug eteplirsen

9 years ago
R&D

Bris­tol-My­ers’ nivolum­ab grabs its sixth break­through des­ig­na­tion as new links to au­toim­mune dis­eases creep up

9 years ago

Scor­ing the 5 top phase III drugs in the glob­al pipeline

9 years ago
R&D

IPO bound? CRISPR Ther­a­peu­tics ups B round to a cool $140M

9 years ago
Financing

Medi­va­tion to Sanofi (in trans­la­tion): You don't know beans about can­cer drug de­vel­op­ment(!)

9 years ago

What’s ahead for UK biotechs in the wake of Brex­it? It's not a pret­ty pic­ture

9 years ago

VC gi­ant NEA backs an up­start’s plan to tack­le neu­rode­gen­er­a­tion

9 years ago

Ebo­la! Zi­ka! ATM! In­ovio CEO Kim called out for gam­ing pan­dem­ic pan­ic

9 years ago
People

Zom­bie biotech Eleven Bio sheds staff in the fi­nal wind down

9 years ago

Is Bio­gen the most des­per­ate buy­er scout­ing the biotech mar­ket?

9 years ago

Cel­gene pays $50M to tie up with four big can­cer re­search cen­ters

9 years ago
Deals

Savara hunts cash af­ter dou­bling down on late-stage res­pi­ra­to­ry drugs

9 years ago

No­var­tis takes aim at a slate of block­busters with cheap­er biosim­i­lars

9 years ago
First page Previous page 340341342343
A service from the Financial Times